Feature Image

Medicinal Value of Cannabidiol (CBD)

Cannabidiol, or CBD, is one of the major cannabinoids found in cannabis. Studies have shown it safely and effectively provides a plethora of therapeutic benefits.

Overview of CBD

While cannabis’ tetrahydrocannabinol (THC) is the cannabinoid that gets most of the attention, the relatively recent monumental findings on the therapeutic benefits of cannabidiol (CBD) are finally giving the non-psychoactive compound its due shine. CBD levels vary among different strains of marijuana plants, but breeders are able to create varieties with high levels of CBD.

Findings: Effects of Cannabis on Effects of CBD

Studies have shown that CBD safely and effectively reduces nausea and vomiting, suppresses seizure activity, combats psychosis disorders, contests inflammatory disorders, counters neurodegenerative disorders, fights tumor and cancer cells, and battles anxiety and depression disorders (Fernandez-Ruiz, et al., 2013). Because of these notable effects, CBD shows exciting potential as a treatment option for neuroinflammation disorders, epilepsy, oxidative injury, vomiting and nausea, and anxiety and schizophrenia (Fernandez-Ruiz, et al., 2013).

Alzheimer’s Disease

CBD limits the progression of Alzheimer’s disease by blocking microglial activation and thus providing neuroprotection (Martin-Moreno, et al., 2011) (Ramirez, et al., 2005) (Campbell & Gowran, 2007). The combination of neuroprotective, anti-oxidative and anti-apoptotic effects provided by CBD decreases the oxidative stress associated with Alzheimer’s disease. (Iuvone, et al., 2004).

Amytotraphic Lateral Sclerosis (ALS)

CBD can significantly slow the onset of ALS (Weydt, et al., 2005). In addition, it can help reduce the pain, appetite loss, depression, sleeping problems, spasticity and drooling that can are commonly associated with ALS (Amtmann, et al., 2004) (Carter, Abood, Aggarwal & Weiss, 2010).

Anxiety Disorder

CBD has effects on the limbic and paralimbic areas of the brain to reduce anxiety and has demonstrated the ability to significantly decrease subjective anxiety (Crippa, et al., 2011). It’s also been shown to significantly reduce the anxiety, cognitive impairment and discomfort associated with public speaking in individuals with Generalized Social Anxiety Disorder (SAD) (Bergamaschi, et al., 2011).


With its anti-inflammatory benefits and potent anti-arthritic effects that protect joints, CBD limits the progression of arthritis (Malfait, et al., 2000).

Bone Health

CBD enhances the maturation of collagen, the protein in the bone’s connective tissue that holds the bone together, which in turn significantly improves the strength and the healing process of bones (Kogan, et al., 2015).


CBD inhibits the progression of cancers located in the breast, lung, prostate and colon in animal models, which suggests that it could also be effective at mediating cancer cell death in human subjects (McAllister, Soroceanu & Desprez, 2015) (Orellana-Serradell, et al., 2015) (Ligresti, et al., 2006). It’s been shown to inhibit human breast cancer cell proliferation and invasion, and decrease the gene expression in breast cancer cells, thus lowering tumor aggressiveness and significantly reducing its size (McAllister, et al., 2007). CBD acid (CBDA) has shown the capability of down-regulating invasive human brain cancer cells and therefore preventing their growth (Takeda, et al., 2014) (McAllister, et al., 2011).

Cardiovascular Disease

CBD reduces myocardial dysfunction, cardiac fibrosis, oxidative-nitrative stress, inflammation, cell death, and interrelated signaling pathways, which collectively offers therapeutic benefits in the treatment of cardiovascular diseases (Rajesh, et al., 2010). In addition, administering CBD shortly after a heart attack has been shown to reduce infarct size and myocardial inflammation, thus showing potential as a treatment for myocardial ischemia (Durst, et al., 2007).

Cirrhosis (Liver Disease)

Studies suggest that CBD helps combat cirrhosis progression by assisting in the death of hepatic stellate cells (HSCs), which proliferate and produce excess collagen, causing the accumulation of scarring on the liver (Lim, Devi & Rozenfeld, 2011). CBD has also been shown to restore liver function in mice experiencing liver failure (Abraham, et al., 2011). In addition, CBD provide protection against ischemia reperfusion, the pivotal mechanism of tissue damage in cirrhosis, by reducing the force of key inflammatory pathways and oxidative/nitrative tissue injury (Mukhopadhyay, Rajesh & Pacher, 2011).

Crohn’s Disease (Irritable Bowel Syndrome)

CBD supports anti-inflammation of the digestive track (Esposito, et al., 2013) (De Filippis, et al., 2011). CBD is able to control the pro-inflammatory response caused by the disease (De Filippis, et al., 2011).


CBD has demonstrated both antidepressant and anti-anxiety effects in animal models (de Mello Schier, et al., 2014) (Zanelati, et al., 2010).


CBD has shown to significantly reduce pro-inflammatory cytokines in the bloodstream and the incidence of diabetes in non-obese mice (Weiss, et al., 2006). It’s also been shown to be effective at curtailing the manifestations of the disease (Weiss, et al., 2008). Research has also found that CBD treatments provide significant protection from diabetic retinopathy (El-Remessy, et al., 2006).

Epilepsy and Seizure Disorders

CBD has demonstrated the ability to reduce or even eliminate seizures (Blair, Deshpande & DeLorenzo, 2015) (Rosenberg, Tsien, Whalley & Devinsky, 2015) (Szaflarski & Bebin, 2014) (Devinsky, et al., 2014). Research also finds that cannabis is effective in the treatment of severe pediatric epilepsy disorders like Dravet syndrome, Doose syndrome and Lennox-Gastaut syndrome (Porter & Jacobson, 2013). CBD has also been shown to improve sleep (53%), alertness (71%), and mood (63%) in epileptic children (Hussain, et al., 2015).


CBD helps prevent complications that can occur after a leukemia patient receives a stem cell or bone marrow transplant (Yeshurun, et al., 2015). In addition, it has been found to help cancer patients manage the nausea, vomiting and pain associated with traditional cancer treatments and to stimulate appetite (Guzman, 2003).


CBD is effective at reducing pain associated with a wide variety of conditions, including headache and migraines (Baron, 2015).

Multiple Sclerosis

CBD combats the inflammation associated with multiple sclerosis, therefore providing neuroprotection and limiting the disease’s progression (Kozela, et al, 2011) (Mecha, et al., 2013). CBD effectively reduces the spasticity caused by multiple sclerosis (Collin, et al., 2010). In addition, it has demonstrated the ability to reduce the neuropathic pain associated with multiple sclerosis (Barnes, 2006).


Studies have found that cannabinoids, including CBD contained in cannabis, are effective at treating the more difficult to control symptoms of nausea, as well as preventing anticipatory nausea in chemotherapy patients (Parker, Rock & Limbeer, 2011).


CBD has been shown to cause a significant decrease in body weight gain and reduce lipid levels (Ignatowska-Jankowska, Jankowski & Swiergiel, 2011) (Silvestri, et al., 2015).


CBD has been shown effective at lowering pain levels associated with a wide variety of conditions, including spasticity, headache, migraines, and other acute pain and chronic pain conditions (Jensen, Chen, Furnish & Wallace, 2015) (Baron, 2015).

Parkinson’s Disease

CBD has neuroprotective properties and supports the health of neural cells mitochondria, thus helping to prevent neurodegeneration (da Silva, et al., 2014) (Zuardi, 2008). (Fernandez-Ruiz, et al., 2013). Significant improvements in well being and quality of life scores were found in Parkinson’s disease patients undergoing CBD treatment (Chagas, et al., 2014). CBD may help with those Parkinson’s’ disease patients experiencing psychosis (Zuardi, et al., 2009).

Post-Traumatic Stress Disorder (PTSD)

CBD’s interaction with the cannabinoid receptors (CB1 and CB2) of the endocannabinoid system modulates the release of neurotransmitter that increases a sense of pleasure and initiates alternation of memory processes (Betthauser, Piilz, Vollmer, 2015). CBD can also block the continuous retrieval of the traumatic event, thus enhancing its extension and reducing its associated anxiety (Akirav, 2013) (Trezza & Campolongo, 2013) (Passie, et al., 2012).


CBD has anxiolytic and antipsychotic properties. Schizophrenia patients treated with CBD in trials have shown that CBD is a safe and well-tolerated alternative treatment for schizophrenia (Zuardi, et al., 2006) (Leweke, et al., 2012).

Sickle Cell Anemia

Cannabinoids have shown to be effective at helping curtail the severe pain associated with sickle cell disease (Kohli, et al., 2010) (Howard, et al., 2005).

Spinal Cord Disease

CBD improves bladder control, muscle spasms and spasticity in patients with spinal cord diseases and damage (Wade, et al, 2003).

Spinal Cord Injuries

When administered shortly after a spinal cord injury, CBD stimulates a neuroprotective response to limit damage (Arevalo-Martin, et al., 2012). CBD has shown to improve motor scores following a spinal cord injury (Kwiatkoski, et al, 2012).


Administering CBD shortly after a stroke protects neurons and astrocytes from damage, and therefore leads to improved functional, histological, biochemical, and neurobehavior recovery (Lafuente, et al., 2011).

Traumatic Brain Injury

CBD has shown to provide a neuroprotective effect and limit brain damage following a traumatic brain injury (Castillo, et al., 2010) (Mechoulam & Shohami, 2007) (Pazos, et al., 2013).


Akirav, I. (2013). Targeting the endocannabinoid system to treat haunting traumatic memories. Frontiers in Behavioral Neuroscience, 7, 124. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776936/.

Amtmann, D., Weydt, P., Johnson, KL., Jensen, MP. And Carter, GT. (2004). Survey of cannabis use in patients with amyotrophic lateral sclerosis. The American Journal of Hospice and Palliative Care, 21(2), 94-104. Retrieved from http://journals.sagepub.com/doi/pdf/10.1177/104990910402100206.

Arevalo-Martin, A., Garcia-Ovejero, D., Sierra, Palomares, Y., Paniagua-Torija, B., Gonzalez-Gil, I., Oretega-Gutierrez, S. and Molina-Holgado, E. (2012). Early endogenous activation of CB1 and CB2 receptors after spinal cord injury is a protective response involved in spontaneous recovery. PLos One, 7(11), e49057. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496738/.

Avraham, Y., Grigoriadis, N., Poutahidis, T., Vorobiev, L., Magen, I., Ilan, Y., Mechoulam, R., and Berry, E. (2011, April). Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice. British Journal of Pharmacology, 162(7), 1650-8. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057300/.

Barnes, M.P. (2006, April). Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opinion on Pharmacotherapy, 7(5), 607-15. Retrieved from http://www.tandfonline.com/doi/full/10.1517/14656566.7.5.607?needAccess=true.

Baron, E.P. (2015, June). Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It’s Been. Headache, 55(6), 885-916. Retrieved from http://onlinelibrary.wiley.com/wol1/doi/10.1111/head.12570/full.

Bergamaschi, M.M., Queiroz, R.H., Chagas, M.H., de Oliveira, D.C., De Martinis, B.S., Kapczinski, F., Quevedo, J., Roesler, R., Schroder, N., Nardi, A.E., Martin-Santos, R., Hallak, J.E., Zuardo, A.W., and Crippa, J.A. (2011, May). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology, 36(6), 1219-26. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079847/.

Bergamaschi, M.M., Queiroz, R.H., Zuardi, A.W., and Crippa, J.A. (2011, September 1). Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent. Current Drug Safety, 6(4), 237-49. Retrieved from http://www.eurekaselect.com/75752/article.

Betthauser, K., Pilz, J., and Vollmer, LE. (2015, August). Use and effects of cannabinoids in military veterans with posttraumatic stress disorder. American Journal of Health-System Pharmacy, 72(15), 1279-84. Retrieved from http://www.ajhp.org/content/72/15/1279.long.

Blair, R.E., Deshpande, L.S., and  DeLorenzo, R.J. (2015, September). Cannabinoids: is there a potential treatment role in epilepsy? Expert Opinion on Pharmacology, 16(13), 1911-4. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845642/.

Campbell, V.A., and Gowran, A. (2007, November). Alzheimer’s disease, taking the edge off with cannabinoids? British Journal of Phamacology, 152(5), 655-662. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2190031/.

Campos, A.C., Ferreira, F.R., and Guimaraes, F.S. (2012, November). Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5Ht1A receptors. Journal of Psychiatric Research, 46(11), 1501-10. Retrieved from http://www.journalofpsychiatricresearch.com/article/S0022-3956(12)00245-2/fulltext.

Carter, GT., Abood, ME., Aggarwal, SK and Weiss, MD. (2010). Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. American Journal of Hospice & Palliative Medicine, 27(5), 347-356. Retrieved from http://journals.sagepub.com/doi/pdf/10.1177/1049909110369531.

Castillo, A., Tolon, M.R., Fernandez-Ruiz, J., Romero, J., Martinez-Orgado, J. (2010, February). The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiology of Disease, 37(2), 434-40. Retrieved from http://www.sciencedirect.com/science/article/pii/S096999610900309X.

Chagas, M.H., Eckeli, A.L., Zuardi, A.W., Pena-Pereira, M.A., Sobreira-Neto, M.A., Sobreira, E.T., Camilo, M.R., Bergamaschi, M.M., Schenck, C.H., Hallack, J.E., Tumas, V., and Crippa, J.A. (2014, October). Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case serious. Journal of Clinical Pharmacy and Therapeutics, 39(5), 564-6. Retrieved from http://onlinelibrary.wiley.com/wol1/doi/10.1111/jcpt.12179/full.

Chagas, M.H., Zuardi, A.W., Tumas, V., Pena-Pereira, M.A., Sobreira, E.T., Bergamaschi, M.M., dos Santos, A.C., Teixeira, A.L., Hallak, J.E., and Crippa, J.A. (2014, November). Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. Journal of Psychopharmacology, 29(11), 1088-98. Retrieved from http://journals.sagepub.com/doi/pdf/10.1177/0269881114550355.

Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O’Leary, C., Ratcliffe, S., Novakova, I., Zapletalova, O., Pikova, J., and Ambler, Z. (2010, June). A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurological Research, 32(5), 451-9. Retrieved from http://www.tandfonline.com/doi/pdf/10.1179/016164109X12590518685660?needAccess=true.

Crippa, J.A., Derenusson, G.N., Ferrari, T.B., Wichert-Ana, L., Duran, F.L., Martin-Santos, R., Simoes, M.V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Santos Filho, A., Freitas-Ferrari, M.C., McGuire, P.K., Zuardi, A.W., Busatto, G.F., and Hallak, J.E. (2011, January). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology, 25(1), 121-30. Retrieved from http://journals.sagepub.com/doi/pdf/10.1177/0269881110379283.

da Silva, V.K., de Freitas, B.S., da Silva Dornelles, A., Nery, L.R., Falavigna, L., Ferreira, R.D., Bogo, M.R., Hallak, J.E., Zuardi, A.W., Crippa, J.A., and Schroder, N. (2014, February). Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection. Molecular Neurobiology, 49(1), 222-33. Retrieved from http://link.springer.com/article/10.1007%2Fs12035-013-8514-7.

De Filippis, D., Esposito, G., Cirillo, C., Cipriano, M., De Winter, B.Y., Scuderi, C., Sarnellil, G., Cuomo, R., Steardo, L., De Man, J.g., and Iuvone, T. (2011). Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS One, 6(12), e28159. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232190/.

de Mello Schier, A.R., de Oliveira Ribeiro, N.P., Coutinho, D.S., Machado, S., Arias-Carrion, O., Crippa, J.A., Zuardi, A.W., Nardi, A.E., and Silva, A.C. (2014). Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS & Neurological Disorders Drug Targets, 13(6), 953-60. Retrieved from http://www.eurekaselect.com/122699/article.

Devinsky, O., Cilio, M.R., Cross, H., Fernandez-Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras-Asward, D., Notcutt, W.G., Martinez-Orgado, J., Robson, P.J., Rohrback, B.G., Thiele, E., Whalley, B., and Friedman, D. (2014, June). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 55(6), 791-802. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707667/.

Durst, R., Danenberg, H., Gallily, R., Mechoulam, R., Meir, K., Grad, E., Beeri, R., Pugatsch, T., Tarsish, E., and Lotan, C. (2007, December). Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. American Journal of Physiology: Heart and Circulatory Physiology, 293(6), H3602-7. Retrieved from http://ajpheart.physiology.org/content/293/6/H3602.long.

Elmes, M.W., Kaczocha, M., Berger, W.T., Leung, K., Ralph, B.P., Wang, L., Sweeney, J.M., Miyauchi, J.T., Tsirka, S.E., Ojima, I., and  Deutsch, D.G. (2015). Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD). The Journal of Biological Chemistry, 290(14), 8711–8721. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423662/.

El-Remessy, A.B., Al-Shabrawey, M., Khalifa, Y., Tsai, N.T., Caldwell, R.B., and Liou, G.I. (2006, January). Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. American Journal of Pathology, 168(1), 235-44. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1592672/.

Esposito, G., Filippis, D.D., Cirillo, c., Iuvone, t., Capoccia, E., Scuderi, C., Steardo, A., Cuomo, R., and Steardo, L. (2013, May). Cannabidiol in inflammatory bowel diseases: a brief overview. Phytotherapy Research, 27(5), 633-6. Retrieved from http://onlinelibrary.wiley.com/wol1/doi/10.1002/ptr.4781/full.

Fernandez-Ruiz, J., Sagredo, O., Pazos, M.R., Garcia, C., Pertwee, R., Mechoulam, R., and Martinez-Orgado, J. (2013, February). Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? British Journal of Clinical Pharmacology, 75(2), 323-33. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579248/.

Guzman, M. (2003, October). Cannabinoids: potential anticancer agents. Nature Reviews, 3(10), 745-55. Retrieved from http://www.nature.com/nrc/journal/v3/n10/full/nrc1188.html.

Howard, J., Anie, KA., Holdcroft, A., Korn, S. and Davies, SC. (2005, October). Cannabis use in sickle cell disease: a questionnaire study. British Journal of Haematology, 131(1), 123-8. Retrieved from http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2005.05723.x/full.

Hussain, SA., Zhou, R., Jacobson, C., Weng, J., Cheng, E., Lay, J., Hung, P., Lerner, JT., and Sankar, R. (2015, June). Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy & Behavior, 47, 138-41. Retrieved from http://www.epilepsybehavior.com/article/S1525-5050(15)00157-2/fulltext.

Ignatowska-Jankowska, B., Jankowski, M.M., and Swiergiel, A.H. (2011, February 18). Cannabidiol decreases body weight gain in rats: involvement of CB2 receptors. Neuroscience Letters, 490(1), 82-4. Retrieved from http://www.sciencedirect.com/science/article/pii/S0304394010015776.

Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., and Izzo, A.A. (2004, April). Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. Journal of Neurochemistry, 89(1), 134-41. Retrieved from http://onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.2003.02327.x/full.

Jensen, B., Chen, J., Furnish, T., and Wallace, M. (2015, October). Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence. Current Pain and Headache Reports, 19(10), 524. Retrieved from http://link.springer.com/article/10.1007%2Fs11916-015-0524-x.

Kogan, N. M., Melamed, E., Wasserman, E., Raphael, B., Breuer, A., Stok, K. S., Sondergaard, R., Escudero, A. V., Baraghithy, S., Attar-Namdar, M., Friedlander-Barenboim, S., Mathavan, N., Isaksson, H., Mechoulam, R., Müller, R., Bajayo, A., Gabet, Y. and Bab, I. (2015). Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts. Journal of Bone and Mineral Research. doi: 10.1002/jbmr.2513. Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/jbmr.2513/full.

Kohli, DR., Li, Y., Khasabov, SG., Gupta, P., Kehl, LJ., Ericson, ME., Nguyen, J., Gupta, V., Hebbel, RP., Simone, DA. and Gupta, K. (2010, July 22). Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids. Blood, 116(3), 456-65. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913454/.

Kozela, E., Lev., N., Kauschansky, N., Eilam, R., Rimmerman, N., Levy, R., Ben-Nun, A., Juknat, A., and Vogel, Z. (2011, August). Cannabidiol inhibits pathogentic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL-6 mice. British Journal of Pharmacology, 163(7), 1507-19. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165959/.

Kwiatkoski, M., Guimaraes, F.S., Del-Bel, E. (2012, April). Cannabidiol-treated rats exhibited higher motor score after cryogenic spinal cord injury. Neurotoxicity Research, 21(3), 271-80. Retrieved from http://link.springer.com/article/10.1007%2Fs12640-011-9273-8.

Lafuente, H., Alvarez, F.J., Pazos, M.R., Alvarez, A., Rey-Santano, M.C., Mielgo, V., Murgia-Esteve, X., Hilario, E., and Martinez-Orgado, J. (2011, September). Cannabidiol reduces brain damage and improves functional recovery after acute hypoxia-ischemia in newborn pigs. Pediatric Research, 70(3), 272-7. Retrieved from http://www.nature.com/pr/journal/v70/n3/full/pr2011171a.html.

Laprairie, R.B., Bagher, A.M., Kelly, M.E.M., and Denovan‐Wright, E.M. (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. British Journal of Pharmacology, 172(20), 4790–4805. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621983/.

Leweke, F.M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C.W., Hoyer, C., Klosterkotter, J., Hellmich, M, and Koeth, D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translation Psychiatry, 2, e94. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316151/.

Ligresti, A., Moriello, A.S., Starowicz, K., Matias, I., Pisanti, S., De Petrocellis, L., Laezza, C., Portella, G., Bifulco, M., and Di Marzo, V. (2006, September). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. Journal of Pharacologogy and Experimental Therapeutics, 318(3), 1375-87. Retrieved from http://jpet.aspetjournals.org/content/318/3/1375.long.

Lim, M.P., Devi, L.A., and Rozenfeld, R. (2011). Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis. Cell Death & Disease. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168994/.

Maa, E. and Figi, P. (2014, June). The case for medical marijuana in epilepsy. Epilepsia, 55(6), 783-6. Retrieved from http://onlinelibrary.wiley.com/doi/10.1111/epi.12610/full.

Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proceedings of the National Academy of Sciences of the United States of America, 97(17), 9561–9566. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC16904/.

Marcu, J.P., Christian, R.T., Lau, D., Zielinski, A.J., Horowitz, M.P., Lee, J., Pakdel, A., Allison, J., Limbad, C., Moore, D.H., Yount, G.L., Desprez, P.Y, and McAllister, S.D. (2010). Cannabidiol enhances the inhibitory effects of Δ9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Molecular Cancer Therapeutics, 9(1), 180–189. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806496/.

Martin-Moreno, A.M., Reigada, D., Ramirez, B.G., Mechoulam, R., Innamorato, N., Cuadrado, A., and de Ceballos, M.L. (2011, June). Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer’s disease. Molecular Pharmacology, 79(6), 964-73. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102548/.

McAllister, S.D., Christian, R.t., Horowitz, M.P., Garcia, A., and Desprez, P.Y. (2007, November). Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Molecular Cancer Therapeutics, 6(11), 2921-7. Retrieved from http://mct.aacrjournals.org/content/6/11/2921.long.

McAllister, S.D., Murase, R., Christian, R.T., Lau, D., Zielinski, A.J., Allison, J., Almanza, C., Pakdel, A., Lee, J., Limbad, C., Liu, Y, Debs, R.J., Moore, D.H., and Desprez, P.Y. (2011, August). Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Research and Treatment, 129(1), 37-47. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3410650/.

McAllister, S.D., Soroceanu, L., and Desprez, P.Y. (2015, June). The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids. Journal of Neuroimmune Pharmacology, 10(2), 255-67. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470774/.

Mecha, M., Feliu, A., Inigo, P.M., Mestre, L., Carrillo-Salinas, F.J., and Guaza, C. (2013, November). Cannabidiol provides long-lasting protection against the deletrious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors. Neurobiology of Disease, 59, 141-50. Retrieved from http://www.sciencedirect.com/science/article/pii/S0969996113001939.

Mechoulam, R., and Shohami, E. (2007, August). Endocannabinoids and traumatic brain injury. Molecular Neurobiology, 36(1), 68-74. Retrieved from http://link.springer.com/article/10.1007/s12035-007-8008-6.

Merrick, J., Lane, B., Sebree, T., Yaksh, T., O’Neill, C., and Banks, S.L. (2016, April). Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid. Cannabis and Cannabinoid Research, 1(1), 102-112. Retrieved from http://online.liebertpub.com/doi/full/10.1089/can.2015.0004.

Mukhopadhyay, P., Monanraj, R., and Pacher, P. (2011, May 15). Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radical Biology & Medicine, 50(10), 1368-1381. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3081988/.

Nicholson, A.N., Turner, C., Stone, B.M., and Robson, P.J. (2004, June). Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. Journal of Clinical Psychopharmacology, 24(3), 305-13. Retrieved from http://journals.lww.com/psychopharmacology/pages/articleviewer.aspx?year=2004&issue=06000&article=00011&type=abstract.

Orellana-Serradell, O., Poblete, CE., Sanchez, C., Castellon, E.A., Gallegos, I., Huidobro, C., Llanos, M.N., and Contreras, H.R. (2015, April). Proapoptotic effect of endocannabinoids in prostate cancer cells. Oncology Reports, 33(4), 1599-608. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358087/.

Parker, L.A., Rock, EM., and Limbeer, C.L. (2011, August). Regulation of nausea and vomiting by cannabinoids. British Journal of Pharmacology, 163(7), 1411-22. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883513/.

Passie, T., Emrich, HM., Karst, M., Brandt, SD. and Halpern, JH. (2012, July-August). Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence. Drug Testing and Analysis, 4(7-8), 649-59. Retrieved from http://onlinelibrary.wiley.com/wol1/doi/10.1002/dta.1377/full.

Pazos, M.R., Mohammed, N., Lafuente, H., Santos, M., Martinez-Pinilla, E., Moreno, E., Valdizan, E., Romero, J., Pazos, A., Franco, R., Hillard, C.J., Alvarez, F.J., Martinez-Orgado, J. (2013, August). Mechanisms of cannabidiol neuroprotection in hyopoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. Neuropharmacology, 71, 282-91. Retrieved from http://www.sciencedirect.com/science/article/pii/S0028390813001238.

Porter, B.E., and Jacobson, C. (2013, December). Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy & Behavior, 29(3), 574-7. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157067/.

Rajesh, M., Mukhopadhyay, P., Batkai, S., Patel, V., Saito, K., Matsumoto, S., Kashiwaya, Y., Horvath, B., Mukhopadhyay, B., Becker, L., Hasko, G., Liaudet, L., Wink, D.A., Veves, A., Mechoulam, R., and Pacher, P. (2010, December 14). Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. Journal of the American College of Cardiology, 56(25), 2115-25. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3026637/.

Ramirez, B.G., Blazquez, C., Gomez del Pulgar, T., Guzman, M., and de Ceballos, M.L. (2005, February). Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. Journal of Neuroscience, 25(8), 1904-13. Retrieved from http://www.jneurosci.org/content/25/8/1904.long.

Rosenberg, EC., Tsien, RW, Whalley, BJ., and Devinsky, O. (2015, August 18). Cannabinoids and Epilepsy. Neurotherapeutics, 12(4). Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604191/.

Russo, E., and Guy, G.W. (2006). A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Medical Hypotheses, 66(2), 234-46. Retrieved from http://www.medical-hypotheses.com/article/S0306-9877(05)00431-7/abstract.

Silvestri, C., Paris, D., Martella, A., Melck, D., Guadagnino, I., Cawthorne, M., Motta, A., and Di Marzo, V. (2015, June). Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis. Journal of Heptology, 62(6), 1382-900. Retrieved from http://www.journal-of-hepatology.eu/article/S0168-8278(15)00003-3/fulltext.

Szaflarski, JP. and Bebin, EM. (2014, December). Cannabis, cannabidiol, and epilepsy–from receptors to clinical response. Epilepsy & Behavior, 41, 277-82. Retrieved from http://www.epilepsybehavior.com/article/S1525-5050(14)00413-2/fulltext.

Takeda, S., Okazaki, H., Ikeda, E., Abe, S., Yoshioka, Y, Watanabe, K., and Aramaki, H. (2014). Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells. The Journal of Toxicological Sciences, 39(5), 711-6. Retrieved from https://www.jstage.jst.go.jp/article/jts/39/5/39_711/_pdf.

Thomas, A., Baillie, G.L., Phillips, A.M., Razdan, R.K., Ross, R.A., and Pertwee, R.G. (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. British Journal of Pharmacology, 150(5), 613–623. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2189767/.

Trezza, V., and Campolongo, P. (2013, August 9). The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD). Frontiers in Behavioral Neuroscience, 7, 100. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739026/.

Van Klingeren, B., and Ten Ham, H. (1976). Antibacterial activity of Δ9-­tetrahydrocannabinol and cannabidiol. Antonie Van Leeuwenhoek, 42(1-2), 9-12. Retrieved from http://link.springer.com/article/10.1007/BF00399444.

Wade, D.T., Robson, P., House, H., Makela, P., and Aram, J. (2003, February). A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical Rehabilitation, 17(1), 21-9. Retrieved from http://journals.sagepub.com/doi/pdf/10.1191/0269215503cr581oa.

Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., and Gallily, R. (2006, March). Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity, 39(2), 143-51. Retrieved from http://www.tandfonline.com/doi/full/10.1080/08916930500356674?needAccess=true.

Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R., and Gallily, R. (2008, January). Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology, 54(1), 244-9. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270485/.

Weydt, P., Hong, S., Witting, A., Moller, T., Stella, N. and Kliot, M. (2005). Cannabidiol delays symptom onset in SOD1 transgenic mice without affecting survival. Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders, 6(3), 182-184. Retrieved from http://www.tandfonline.com/doi/abs/10.1080/14660820510030149?journalCode=iafd19.

Yeshurun, M., Shpilberg, O., Herscovici, C., Shargian, L., Dreyer, J., Peck, A., Israeli, M., Levy-Assaraf, M., Gruenewald, T., Mechoulam, R., Raanani, P., and Ram, R. (2015, October). Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study. Biology of Blood and Marrow Transplantation, 21(10), 1770-5. Retrieved from http://www.bbmt.org/article/S1083-8791(15)00375-4/fulltext.

Zanelati, T.V., Biojone, C., Moreira, F.A., Guimaraes, F.S., and Joca, S.R. (2010, January). Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. British Journal of Pharmacology, 159(1), 122-8. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823358/.

Zhornitsky, S., and Potvin, S. (2012). Cannabidiol in Humans—The Quest for Therapeutic Targets. Pharmaceuticals, 5(5), 529–552. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763649/.

Zuardi, A.W., Shirakawa, I., Finkelfarb, E., and Karniol, I.G. (1982). Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology, 76(3), 245-50. Retrieved from https://goo.gl/46mS74.

Zuardi, A.W., Crippa, J.A., Hallak, J.E., Moreira, F.A., and Guimaraes, F.S. (2006, April). Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Brazilian Journal of Medical and Biological Research, 39(4), 421-9. Retrieved from http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000400001&lng=en&nrm=iso&tlng=en.

Zuardi, A.W., Crippa, J.A., Hallak, J.E., Pinto, J.P., Chagas, M.H., Rodrigues, G.g., Dursun, S.M., and Tumas, V. (2009, November). Cannabidiol for the treatment of psychosis in Parkinson’s disease. Journal of Psychopharmacology, 23(8), 979-83. Retrieved from http://journals.sagepub.com/doi/pdf/10.1177/0269881108096519.

Zuardi, A.W., (2008, September). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Revista Brasileira De Psiquiatria, 30(3), 271-80. Retrieved from http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462008000300015&lng=en&nrm=iso&tlng=en.

  • October 26, 2015
  • Brenda Clement

    Can CBD Hemp oil help people with Parkinson De.?